Trevi Therapeutics, Inc.
TRVI- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001563880
In the last 90 days, Trevi Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 218 institutions reported holding it in 13F filings for Q2 2026, worth $2.76B in total; Viking Global Investors is the only superinvestor holding it.
13F holders, Q1 2026
Institutional positions in Trevi Therapeutics, Inc. as of Mar 31, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 198
- +16 vs. Q4 2025
- Shares held
- 134.9M
- +11.1M (+9.0%) vs. Q4 2025
- Total value
- $1.61B
- +$60.9M (+3.9%) vs. Q4 2025
- New holders
- 41
- 65 more added
- Sold out
- 25
- 62 more reduced
2 institutions that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting TRVI on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 218 | $2.76B |
| Q1 2026 | 198 | $1.61B |
| Q4 2025 | 184 | $1.63B |
| Q3 2025 | 164 | $1.18B |
| Q2 2025 | 154 | $627.2M |
| Q1 2025 | 137 | $554.3M |
| Q4 2024 | 110 | $329.5M |
| Q3 2024 | 93 | $194.1M |
| Q2 2024 | 77 | $166.6M |
| Q1 2024 | 80 | $177.9M |
| Q4 2023 | 63 | $70.0M |
| Q3 2023 | 55 | $106.1M |
| Q2 2023 | 53 | $116.7M |
| Q1 2023 | 36 | $80.4M |
| Q4 2022 | 37 | $83.3M |
| Q3 2022 | 40 | $70.5M |
| Q2 2022 | 32 | $80.8M |
| Q1 2022 | 23 | $32.9M |
| Q4 2021 | 17 | $10.3M |
| Q3 2021 | 18 | $17.4M |
| Q2 2021 | 17 | $28.1M |
| Q1 2021 | 19 | $35.6M |
Institutions, Q1 2026
Shares, value and share of portfolio for each institution holding Trevi Therapeutics, Inc.; share changes are against Q4 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| StemPoint Capital LP | 0 | $0 | 0.00% | −399,557−100.0% | Sold out |
| Velan Capital Investment Management LP | 0 | $0 | 0.00% | −205,000−100.0% | Sold out |
| Fred Alger Management, LLC | 0 | $0 | 0.00% | −157,980−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −125,104−100.0% | Sold out |
| Rosalind Advisors, Inc. | 0 | $0 | 0.00% | −100,000−100.0% | Sold out |
| Allianz Asset Management GmbH | 0 | $0 | 0.00% | −52,800−100.0% | Sold out |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −45,995−100.0% | Sold out |
| Verition Fund Management LLC | 0 | $0 | 0.00% | −32,119−100.0% | Sold out |
| Fox Run Management, L.L.C. | 0 | $0 | 0.00% | −31,346−100.0% | Sold out |
| Qube Research & Technologies Ltd | 0 | $0 | 0.00% | −22,622−100.0% | Sold out |
| Axq Capital, LP | 0 | $0 | 0.00% | −22,204−100.0% | Sold out |
| Dymon Asia Capital (Singapore) Pte. Ltd. | 0 | $0 | 0.00% | −20,000−100.0% | Sold out |
| Abel Hall, LLC | 0 | $0 | 0.00% | −10,191−100.0% | Sold out |
| DLD Asset Management, LP | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |
| Quest Partners LLC | 0 | $0 | 0.00% | −7,988−100.0% | Sold out |
| Bellevue Group AG | 0 | $0 | 0.00% | −7,603−100.0% | Sold out |
| Amalgamated Bank | 0 | $0 | 0.00% | −2,852−100.0% | Sold out |
| Aquatic Capital Management LLC | 0 | $0 | 0.00% | −1,978−100.0% | Sold out |
| Bessemer Group Inc | 0 | $0 | 0.00% | −1,560−100.0% | Sold out |
| Aster Capital Management (DIFC) Ltd | 0 | $0 | 0.00% | −602−100.0% | Sold out |
| Daiwa Securities Group Inc. | 0 | $0 | 0.00% | −427−100.0% | Sold out |
| SRS Capital Advisors, Inc. | 0 | $0 | 0.00% | −206−100.0% | Sold out |
| SageView Advisory Group, LLC | 0 | $0 | 0.00% | −49−100.0% | Sold out |
| Vanguard Group Inc | – | – | – | – | Not filed |
| Comerica Bank | – | – | – | – | Not filed |